North America Adalimumab Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Dec 2020
  • North America
  • 350 Pages
  • No of Tables: 87
  • No of Figures: 55

North America Adalimumab Market, By Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Parenteral, Oral), Population Type (Adults, Children), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2027

North America Adalimumab MarketMarket Analysis and Insights: North America Adalimumab Market

North America Adalimumab market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.9% in the forecast period of 2020 to 2027 and is expected to reach USD 21,956.98 million by 2027. Presence of reimbursement and rise in the prevalence of rheumatoid arthritis are the major drivers which propelled the demand of the market in the forecast period mentioned above.

Adalimumab is one of the monoclonal antibodies and is used for the treatment of certain autoimmune diseases involving rheumatoid arthritis and crohn's diseases among others. Adalimumab is an anti- TNF drug indicated for the treatment of inflammatory symptoms. The biologic of adalimumab is humira and various biosimilar drugs of humira are also available which involves exemptia, hyrimoz, cyltezo and hulio among several others. Adalimumab works by binding to the TNF factor-alpha which reduces the chances of the inflammatory response to autoimmune diseases.

Adalimumab comprises features such as increasing need for better therapeutics options which will impact in launching new product by the manufacturers into the market which enhance its demand as well as increasing investment in research and development leads to the adalimumab market growth. Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative adalimumab which is expected to provide various other opportunities in the adalimumab market. However, high cost of drugs and side effects of drugs are expected to restraint the adalimumab market growth in the forecast period.

The adalimumab market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Adalimumab Market Adalimumab Market Scope and Market Size

Adalimumab market is segmented on the based on the basis of indication, type, dosage strength, drug type, route of administration, population type, end - user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of indication, the adalimumab market the market is segmented into rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, hidradenitis suppurativa, non-infectious intermediate and others. In 2020, rheumatoid arthritis segment is dominating the market because of increasing population of patients suffering from rheumatoid arthritis. Along with this increasing geriatric population is another factor responsible for accelerating the growth of rheumatoid arthritis segment.   
  • On the basis of type, the adalimumab market is segmented into biologics and biosimilars. In 2020, biologics segment is dominating the market because of the wide distribution network of Humira, a biologic drug.
  • On the basis of dosage strength, the adalimumab market is segmented into 40mg/0.4ml, 80mg/0.8ml, 20mg/0.4ml, 10mg/0.1ml, and others. In 2020, 40mg/0.4ml is dominating the market because majority of population or patients are prescribed by the 40mg/0.4ml of drug dosage in order to achieve first line of therapy for inflammatory diseases.
  • On the basis of drug type, the adalimumab market is segmented into branded and generics. In 2020, branded segment is dominating the market because patients are more assured with the branded product; moreover the branded Humira is preferred by healthcare professionals all over the world.
  • On the basis of route of administration, the adalimumab market is segmented into parenteral, and oral. In 2020, parenteral segment is dominating the market because adalimumab is only b given through SC route so as to induce slow and effective long term systemic effect.
  • On the basis of population type, the adalimumab market is segmented into adults, children. In 2020, adults segment is dominating the market because adult populations have weak immune system and thus are more prone to inflammatory diseases.
  • On the basis of end user, the adalimumab market is segmented into hospitals, specialty clinics, home healthcare, and others. In 2020, hospitals segment is dominating the market because of the presence of skilled professionals and best insurance coverage policies.  
  • On the basis of distribution channel, the adalimumab market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, direct tenders, others. In 2020, hospital pharmacies dominating the market because adalimumab is only prescribed by the doctors, so most of the patients visited to hospital procures adalimumab from nearby hospital pharmacies.

Adalimumab Market Country Level Analysis

The adalimumab market is analyzed and market size information is provided by country, indication, type, dosage strength, drug type, route of administration, population type, and end-user and distribution channel as referenced above.

The countries covered in the adalimumab market report are the U.S., Canada, and Mexico.

The U.S. is dominating the market in North America because Humira (Adalimumab) is one of the bestselling drugs in the market

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Geriatric Population and Increasing Number of Contract Research Organizations are Boosting the Market Growth of Adalimumab

Adalimumab market also provides you with detailed market analysis for every country growth in Adalimumab industry with Adalimumab drugs sales, impact of advancement in the Adalimumab technology and changes in regulatory scenarios with their support for the Adalimumab market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Adalimumab Market Share Analysis

Adalimumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to adalimumab market.

The major companies which are dealing in the adalimumab are AbbVie Inc., CELLTRION INC., Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila, Hetero Biopharma Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the adalimumab market.

For instance,

  • In September 2020, Innovent Biologics, Inc. received marketing approval for SULINNO in China. SULINNO is an adalimumab injection indicated for treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis. This has been estimated that approximately 20 million people in China suffer from rheumatoid arthritis, psoriasis and ankylosing spondylitis. This product approval thus helped the company to boost up its product portfolio and to generate more revenue.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the adalimumab market which also provides the benefit for organization to improve their offering for adalimumab.

Customization Available: North America Adalimumab Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 NORTH AMERICA ADALIMUMAB MARKET, PIPELINE ANALYSIS

TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.

TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)

TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS

TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT

TABLE 6 NORTH AMERICA ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)

TABLE 7 NORTH AMERICA RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 NORTH AMERICA CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 NORTH AMERICA CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 NORTH AMERICA ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 NORTH AMERICA PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 14 NORTH AMERICA HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 15 NORTH AMERICA NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 NORTH AMERICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 NORTH AMERICA ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 18 NORTH AMERICA BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 19 NORTH AMERICA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 20 NORTH AMERICA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 21 NORTH AMERICA ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)

TABLE 22 NORTH AMERICA 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 NORTH AMERICA 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 NORTH AMERICA 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 NORTH AMERICA 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 NORTH AMERICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 NORTH AMERICA ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

TABLE 28 NORTH AMERICA BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 NORTH AMERICA GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 NORTH AMERICA GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 31 NORTH AMERICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)

TABLE 32 NORTH AMERICA PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 NORTH AMERICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)

TABLE 34 NORTH AMERICA ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 NORTH AMERICA CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 NORTH AMERICA ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 37 NORTH AMERICA HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 NORTH AMERICA SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 NORTH AMERICA HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 NORTH AMERICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 NORTH AMERICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 42 NORTH AMERICA HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 NORTH AMERICA RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 NORTH AMERICA ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 NORTH AMERICA DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 46 NORTH AMERICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 NORTH AMERICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 48 NORTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 49 NORTH AMERICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 NORTH AMERICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 NORTH AMERICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 52 NORTH AMERICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 53 NORTH AMERICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 54 NORTH AMERICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 55 NORTH AMERICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 56 NORTH AMERICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 57 NORTH AMERICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 U.S. ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 59 U.S. ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 60 U.S. BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 U.S. ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 62 U.S. ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 63 U.S. GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 64 U.S. ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 65 U.S. ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 66 U.S. ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 67 U.S. ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 68 CANADA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 69 CANADA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 CANADA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 CANADA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 72 CANADA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 73 CANADA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 74 CANADA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 75 CANADA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 76 CANADA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 77 CANADA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 78 MEXICO ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 79 MEXICO ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 MEXICO BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 MEXICO ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 82 MEXICO ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 83 MEXICO GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 84 MEXICO ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 85 MEXICO ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 86 MEXICO ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 87 MEXICO ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions